UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Inhaled nitric oxide in adults: Biology and indications for use

Author
Jess Mandel, MD
Section Editor
Polly E Parsons, MD
Deputy Editor
Geraldine Finlay, MD

INTRODUCTION

Nitric oxide (NO) is a naturally occurring vasodilator. In patients with pulmonary arterial hypertension (PAH), inhaled NO has an established role in vasoreactivity testing. Inhaled NO has also been proposed as a long-term therapy for PAH and possibly other types of pulmonary hypertension (PH) [1], and is occasionally used as a rescue therapy for severely hypoxemic patients both with and without an established diagnosis of PH.

The role of inhaled NO in vasoreactivity testing and therapeutic uses of this agent in adults are discussed in this topic review. The use of inhaled NO in the management of infants with persistent PH and the role of exhaled NO in asthma and other chronic lung diseases are discussed separately. (See "Persistent pulmonary hypertension of the newborn", section on 'Inhaled nitric oxide' and "Exhaled nitric oxide analysis and applications".)

BIOLOGY AND PHARMACOKINETICS

Endogenous NO is produced from L-arginine in vascular endothelial cells by endothelial nitric oxide synthase (eNOS, type III NOS), a constitutively expressed enzyme [2]. NO is a naturally occurring vasodilator that works with other molecules to determine vascular resistance (systemic and pulmonary) [3,4]. When administered by inhalation, it selectively dilates the pulmonary vasculature, is quick acting, and has a short half-life with minimal systemic symptoms, rendering it a suitable agent for vasoreactivity testing and therapy.

Mechanism of action – NO induces smooth muscle soluble guanylate cyclase to increase cyclic guanosine monophosphate (cGMP). This reduces intracellular calcium levels, causing smooth muscle relaxation (ie, vasodilation) in precapillary resistance arterioles [2,5]. Additional effects of NO include suppression of both smooth muscle proliferation and platelet aggregation [6,7].

These properties have led to the development of inhaled NO and other agents that enhance local NO effects (eg, riociguat, a cGMP enhancer). There appears to be a threshold for pulmonary vasodilation when NO is administered by inhalation, which occurs at a dose of approximately 10 parts per million (ppm) [8-10]. Whether a dose-effect relationship exists has not been clearly defined. Administration of inhaled NO is discussed below. (See 'Procedure' below.)

            

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Apr 2017. | This topic last updated: Feb 28, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. http://clinicaltrials.gov/show/NCT01457781 (Accessed on August 24, 2015).
  2. Gaston B, Drazen JM, Loscalzo J, Stamler JS. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med 1994; 149:538.
  3. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338:1173.
  4. Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation 2004; 109:3106.
  5. Archer SL, Huang JM, Hampl V, et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A 1994; 91:7583.
  6. Zapol WM, Rimar S, Gillis N, et al. Nitric oxide and the lung. Am J Respir Crit Care Med 1994; 149:1375.
  7. Nong Z, Hoylaerts M, Van Pelt N, et al. Nitric oxide inhalation inhibits platelet aggregation and platelet-mediated pulmonary thrombosis in rats. Circ Res 1997; 81:865.
  8. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111.
  9. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151:384.
  10. Pearl JM, Nelson DP, Raake JL, et al. Inhaled nitric oxide increases endothelin-1 levels: a potential cause of rebound pulmonary hypertension. Crit Care Med 2002; 30:89.
  11. Rimar S, Gillis CN. Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation 1993; 88:2884.
  12. Jolliet P, Bulpa P, Thorens JB, et al. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange. Thorax 1997; 52:369.
  13. Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998; 32:1068.
  14. Morales-Blanhir J, Santos S, de Jover L, et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 2004; 98:225.
  15. Leuchte HH, Schwaiblmair M, Baumgartner RA, et al. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 2004; 125:580.
  16. Preston IR, Sagliani KD, Roberts KE, et al. Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension. Pulm Circ 2013; 3:68.
  17. Hill NS, Preston IR, Roberts KE. Inhaled Therapies for Pulmonary Hypertension. Respir Care 2015; 60:794.
  18. Snell GI, Salamonsen RF, Bergin P, et al. Inhaled nitric oxide used as a bridge to heart-lung transplantation in a patient with end-stage pulmonary hypertension. Am J Respir Crit Care Med 1995; 151:1263.
  19. Koh E, Niimura J, Nakamura T, et al. Long-term inhalation of nitric oxide for a patient with primary pulmonary hypertension. Jpn Circ J 1998; 62:940.
  20. Channick RN, Newhart JW, Johnson FW, et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 1996; 109:1545.
  21. Preston IR, Klinger JR, Landzberg MJ, et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001; 120:866.
  22. http://clinicaltrials.gov/show/NCT01457781 (Accessed on August 01, 2013).
  23. Barst RJ, Channick R, Ivy D, Goldstein B. Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension. Pulm Circ 2012; 2:139.
  24. Wanstall JC, Jeffery TK. Recognition and management of pulmonary hypertension. Drugs 1998; 56:989.
  25. Jeffery M, Taichman DB. Management of the acutely ill patient with pulmonary arterial hypertension. In: Pulmonary Vascular Disease, Mandel J, Taichman DB (Eds), Elsevier Science, Philadelphia 2006. p.254.
  26. Mizutani T, Layon AJ. Clinical applications of nitric oxide. Chest 1996; 110:506.
  27. Bhorade S, Christenson J, O'connor M, et al. Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med 1999; 159:571.
  28. De Wet CJ, Affleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 2004; 127:1058.
  29. Meade MO, Granton JT, Matte-Martyn A, et al. A randomized trial of inhaled nitric oxide to prevent ischemia-reperfusion injury after lung transplantation. Am J Respir Crit Care Med 2003; 167:1483.
  30. Cornfield DN, Milla CE, Haddad IY, et al. Safety of inhaled nitric oxide after lung transplantation. J Heart Lung Transplant 2003; 22:903.
  31. Takaba K, Aota M, Nonaka M, et al. Successful treatment of chronic thromboembolic pulmonary hypertension with inhaled nitric oxide after right ventricular thrombectomy. Jpn J Thorac Cardiovasc Surg 2004; 52:257.
  32. Fattouch K, Sbraga F, Sampognaro R, et al. Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study. J Cardiovasc Med (Hagerstown) 2006; 7:119.
  33. Trummer G, Berchtold-Herz M, Martin J, Beyersdorf F. Successful treatment of pulmonary hypertension with inhaled nitric oxide after pulmonary embolectomy. Ann Thorac Surg 2002; 73:1299.
  34. Solina A, Papp D, Ginsberg S, et al. A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. J Cardiothorac Vasc Anesth 2000; 14:12.
  35. Christenson J, Lavoie A, O'Connor M, et al. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am J Respir Crit Care Med 2000; 161:1443.
  36. Rossaint R, Falke KJ, López F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328:399.
  37. Weinberger B, Laskin DL, Heck DE, Laskin JD. The toxicology of inhaled nitric oxide. Toxicol Sci 2001; 59:5.
  38. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999; 91:307.
  39. Narula P, Xu J, Kazzaz JA, et al. Synergistic cytotoxicity from nitric oxide and hyperoxia in cultured lung cells. Am J Physiol 1998; 274:L411.
  40. Ruan SY, Huang TM, Wu HY, et al. Inhaled nitric oxide therapy and risk of renal dysfunction: a systematic review and meta-analysis of randomized trials. Crit Care 2015; 19:137.